ezm0414
·Code: EZM0414
ezm0414: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Epizyme, Inc. (EPZM) | Phase 1 |
Clinical Trials (1)
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Frequently asked questions
Who is developing ezm0414?
ezm0414 is being developed by Epizyme, Inc..
How many clinical trials involve ezm0414?
BioSniper tracks 1 clinical trial involving ezm0414.
Get deeper analysis on ezm0414
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis